Summary
Macrophages measure the ‘eat-me’ signal IgG to identify targets for phagocytosis. We tested if prior encounters with IgG influence macrophage appetite. IgG is recognized by the Fc Receptor. To temporally control Fc Receptor activation, we engineered an Fc Receptor that is activated by light-induced oligomerization of Cry2, triggering phagocytosis. Using this tool, we demonstrate that subthreshold Fc Receptor activation primes mouse bone marrow derived macrophages to be more sensitive to IgG in future encounters. Macrophages that have previously experienced subthreshold Fc Receptor activation eat more IgG-bound human cancer cells. Increased phagocytosis occurs by two discrete mechanisms – a short- and long-term priming. Long-term priming requires new protein synthesis and Erk activity. Short-term priming does not require new protein synthesis and correlates with an increase in Fc Receptor mobility. Our work demonstrates that IgG primes macrophages for increased phagocytosis, suggesting that therapeutic antibodies may become more effective after initial priming doses.
Keywords: macrophage, phagocytosis, Fc Receptor, IgG
Graphical Abstract

eTOC Blurb:
Bond et. al. use optogenetics to show that prior subthreshold Fc Receptor activation increases phagocytosis of future antibody opsonized targets. This priming response lasts at least 72 hours and is associated with increased FcR mobility in the short-term and Erk mediated transcriptional changes in the long-term.
Introduction
Macrophages eat pathogens and infected, cancerous or dying cells via phagocytosis. To select targets for phagocytosis, macrophages measure ‘eat-me’ signals, like IgG antibodies. IgG is recognized by the Fc Receptor (FcR), which is phosphorylated and recruits the kinase Syk, triggering downstream signaling1,2. Therapeutic IgGs like Rituximab or Trastuzumab trigger Antibody-dependent Cellular Phagocytosis (ADCP) or Antibody-dependent Cellular Cytotoxicity (ADCC) to reduce cancer growth2-7. Even many antibodies originally designed to block the function of their target actually activate the FcR for full efficacy8,9. Given the therapeutic importance, there is substantial interest in understanding how to boost macrophage phagocytosis.
What affects macrophage appetite? One important parameter is how sensitive a macrophage is to ‘eat-me’ signals. Antibody-dependent phagocytosis requires the coordinated activation of a sufficient number of FcRs10. Targets with a subthreshold amount of IgG are not phagocytosed, despite triggering the initial steps in the phagocytosis signaling pathway10. In other macrophage signaling pathways, low levels of activating signal do not elicit any response on their own, but prime macrophages for rapid and intense response to future stimuli11. Whether subthreshold FcR signaling has any effect on macrophage appetite is not clear.
During an immune response or treatment with a therapeutic antibody, macrophages encounter multiple potential targets for phagocytosis sequentially, leading to bursts of FcR activation. Some encounters with antibody-opsonized cells result in phagocytosis of the entire cell3,5, but many cells do not have sufficient antibodies to trigger phagocytosis. Instead macrophages may trogocytose, or nibble, a target cell or simply ignore it12-15. In some circumstances, prior phagocytosis increases macrophage appetite16,17. In contrast, other studies demonstrated that phagocytosing several whole cancer cells reduces macrophage appetite18. There is no clear, unifying model explaining these differences, which could be dependent on the specific ‘eat-me’ signal presented, the time since phagocytosis, the intensity of the ‘eat-me’ signal, digestion of the internalized particle, or any number of other factors19.
To unravel how prior IgG exposure affects macrophage appetite, we need to precisely control the timing and intensity of activating specific phagocytic receptors. Delivering a temporally controlled, homogenous antibody stimuli to a population of cells is very difficult with the current tools. Because soluble IgG does not activate the FcR, IgG must be presented on antibody-bound targets. Controlling precisely the number of targets a macrophage encounters, or the timing of these encounters is very difficult and low-throughput.
To quantitatively control the duration and strength of FcR activation, we developed an optogenetic FcR (optoFcR). We found that prior FcR activation primes macrophages for greater responses to subsequent stimuli. Counterintuitively, low levels of optoFcR activation induced stronger priming than high levels of optoFcR activation. Macrophage priming is controlled by two independent mechanisms, one short-term (<1 hour) and one long-term response (starting at 4 hours, and lasting up to 3 days). The short-term response is associated with an increase in FcR mobility, accelerated initiation of phagocytosis and increased phagocytic cup formation. The long-term response requires activation of Erk to drive a transcriptional response which leads to increases in both initiation and completion of phagocytosis. These data suggest that macrophages can integrate signaling from previous encounters with IgG to modify the response to the next target. This study provides insight into how macrophage appetite is regulated, and may suggest strategies to enhance antibody-dependent cellular phagocytosis.
Results
Optogenetic FcR recapitulates native FcR signaling for precise temporal control over signaling
To precisely control the temporal pattern of FcR activation across an entire field of cells, we sought to design an optogenetic FcR that could be turned on and off with light. Prior work has shown that the FcR clusters upon IgG binding. Although the FcR has no inherent kinase activity, clustering promotes phosphorylation of the intracellular Immunoreceptor Tyrosine-based Activation Motifs (ITAMs) and phagocytosis20-22. We hypothesized that clustering may be sufficient to induce FcR activation. To test this, we designed an optoFcR construct that consists of a myristoylation sequence for membrane localization, the intracellular domain for the native FcR ɣ-chain and a light activatable peptide CRY2 (Figure 1a). We selected the variant CRY2olig because it forms multimeric, rapidly reversible clusters23. Upon blue light (450nm) stimulation the optoFcR oligomerizes (Figure 1b; Video S1). Clusters dissociate when the cells are returned to the dark (Figure 1b). Like the native FcR when it is bound to IgG, the optoFcR clusters increased in size and number with more light stimulation, and partially excluded CD45 (Figure S1a-f). Clustering also results in the recruitment of the downstream effector protein Syk, suggesting that clustering is sufficient to induce FcR phosphorylation (Figure 1c,d; Video S2).
Figure 1. Optogenetic Fc Receptor (optoFcR) controls phagocytosis.

a) Schematic of optoFcR design, containing a myristoylation signal for membrane localization, the ITAM-containing intracellular domain from the FcR gamma-chain for signaling, mScarlet fluorophore, and the homo-oligomerizing peptide - cryptochrome 2 (CRY2olig). b) The optoFcR in bone marrow derived macrophages (BMDMs) starts dispersed on the membrane (T0m; n=0/22 cells with visible clusters), and clusters after 15 minutes of constant high intensity light (T15m; n=21/22 cells with visible clusters). The optoFcR is declustered after 30 minutes in the dark (T45m; n=0/22 cells with visible clusters). See also video S1. c) The downstream effector protein, Syk, colocalized with optoFcR in Raw264.7 macrophages stably expressing both the optoFcR and Syk-mNeonGreen. A line scan (right) shows the Syk and optoFcR intensity at the position indicated by the yellow arrow in the inset. See also video S2. d) Graph shows the Pearson’s correlation coefficient for Syk and optoFcR at the cell cortex. Each data point represents an ROI drawn around a membrane region of a cell. The same ROI was used for both T0 (OFF) and T2 (ON), and the data points from the same ROI are connected by a line. e) Schematic of experimental design for f-g. f) optoFcR (green) expressing macrophages and ICAM conjugated beads are visualized by atto390 in the supported lipid bilayer (magenta) before (OFF) and after (ON) 15 min of optoFcR activation with high intensity light. Internalized beads are labeled with a yellow star. See also video S3. g) Quantification of phagocytosis in BMDMs after 15 minutes of optoFcR stimulation at low (5 uW/cm2), medium (90 uW/cm2), and high (1390 uW/cm2) intensity light compared to control cells that do not express the optoFcR but receive the high intensity light stimulus. Each data point represents the mean of an independent experiment. Data collected in the same replicate are denoted by symbol shape. In all graphs, bars represent the mean ±SEM. *indicates p<0.05, ***indicates p<0.0005 using a paired t-test (d), one way ANOVA with dunnett correction (g). Scale bars are 10 um. See also figure S1.
We next sought to determine if clustering of the optoFcR is sufficient to trigger phagocytosis. We incubated ICAM-1 conjugated beads with macrophages expressing either the optoFcR or membrane tethered mCh (mCh-CAAX) and exposed them to 15 min of light stimulation (Figure 1e). ICAM-1 mediates bead binding to the macrophage, but does not trigger phagocytosis of otherwise unopsonized beads24,25. Macrophages expressing the optoFcR engulfed three times as many beads as control macrophages when stimulated with the highest intensity light and twice as many beads when stimulated with medium intensity light (Figure 1f,g; Video S3). Low intensity light did not activate phagocytosis. This dose response is similar to the dose response seen in IgG mediated phagocytosis (Figure S1g-h). Together, these data demonstrate that clustering of the FcR ITAM domain is sufficient to initiate phagocytosis in macrophages without a specific ‘eat-me’ signal.
Prior FcR activation enhances phagocytosis of IgG coated beads.
With the ability to temporally control FcR activation in bone marrow-derived macrophages, we next sought to determine if prior FcR activation influences phagocytic ability. We stimulated macrophages with low intensity blue light to activate the optoFcR for 15 minutes which is around the same timescale that a macrophage interacts with a phagocytic target. We then waited 1 or 12 hours before adding IgG opsonized beads, which is sufficient time for the optoFcR to completely decluster. Then we measured the number of beads engulfed per cell using microscopy (Figure 2a). We found that prior optoFcR activation increased the amount of eating roughly 2-fold compared to cells that either did not receive prior light stimulation or did not express the optoFcR (Figure 2b). This demonstrates that prior FcR activation primes macrophages to respond to future IgG.
Figure 2. Prior FcR activation specifically enhances macrophage sensitivity to IgG.

a) Schematic of experimental design for light-induced priming. Control (mCherry-CAAX) and optoFcR expressing BMDMs were stimulated with light for 15 min. The cells were returned to the dark for either 1 or 12 hours, then targets opsonized with 1 nM IgG (approx. 10-18 IgG molecules/um2) were introduced. After 15 minutes of phagocytosis, beads were washed out. Cells were imaged and the number of targets phagocytosed per cell was counted. b) Quantification of experiment described in (a). OptoFcR expressing cells that received light phagocytosed significantly more than cells that did not receive light, or cells that received light but did not express the optoFcR. c,d) Heat maps of fold change in phagocytosis of 1 nM IgG beads in optoFcR expressing macrophages that received a priming dose of light compared to optoFcR expressing macrophages that did not receive light stimulation. In (c) the intensity and delay time between initial stimulation and bead addition were altered. In (d) the priming dose of light and stimulation time were altered. Data are from 2 independent replicates. e) Schematic of experimental design for priming macrophages with IgG beads. Wildtype BMDMs were given either beads with 0.1 nM or 0 nM IgG for 15 min as a priming stimulus. Those beads were then washed out and the cells were allowed to recover for 1 hr. A second set of different color beads ligated to IgG at the indicated concentration were added and the amount of phagocytosis was determined after 15 min. f) Quantification of phagocytosis for experiment described in (e). Macrophages that were preincubated with 0.1 nM IgG-conjugated beads phagocytosed significantly more than macrophages preincubated with unopsonized beads. g) Phagocytosis of bead targets without an ‘eat-me’ signal. Experiment was performed as described in (a) except the beads did not contain IgG. h) Phagocytosis of bead targets with the efferocytic ‘eat-me’ signal, phosphatidylserine. Experiment was performed as described in (a) except the beads were covered in a 10% phosphatidylserine bilayer to mimic an apoptotic corpse. In all graphs, each point represents the mean of an independent experiment. Data collected in the same replicate are denoted by symbol shape. Bars represent the mean ±SEM. *indicates p<0.05, **indicates p<0.005, ****indicates p<0.0001 by two-way ANOVA with Sidak corrections (b), multiple T-tests with Holm-Sidak corrections (f), and unpaired t-test (g,h). See also figure S2.
Next, we systematically varied the light intensity and stimulation time used to activate the optoFcR as well as the delay between activating the optoFcR and measuring phagocytosis of IgG coated beads. In all cases, we found that low doses of light, and thus less FcR activity, led to the highest macrophage priming (Figure 2c,d). The amount of light that best primed macrophages was not sufficient to activate phagocytosis on its own (Figure 1g). None of the conditions we tested changed the surface expression of activating or inhibiting FcRs or the inhibitory receptor SIRPa (Figure S2a-e). Together, this suggests that a sub-threshold level of FcR activation, not sufficient to activate phagocytosis, primes macrophages for future encounters with IgG.
We then wanted to know if we could induce macrophage priming using IgG and the endogenous FcR. Based on our data from the optoFcR, we predicted that a low level of IgG exposure would enhance phagocytosis of a second dose of IgG-coated beads. To test this, we preincubated macrophages with beads containing an IgG density that did not activate phagocytosis (Figure S1) or unopsonized beads. We then extensively washed the macrophages to remove these beads and added a second color of IgG-bound beads (Figure 2e). We found that macrophages preincubated with IgG-coated beads phagocytosed more than macrophages pre-incubated with unopsonized beads when the second dose was above the threshold for inducing phagocytosis (Figure 2f, Figure S2f). This suggests that the native IgG and FcR system primes macrophages like the optoFcR system.
Prior FcR activation specifically enhances phagocytosis of IgG coated beads, not phosphatidylserine or unopsonized beads.
We next wanted to know if prior FcR activation specifically primed macrophages to phagocytose IgG-coated targets or if it broadly enhanced phagocytosis. We first determined if prior optoFcR activation increased non-specific phagocytosis of unopsonized targets. Primed macrophages did not phagocytose more unopsonized beads than control macrophages (Figure 2g). We then determined if prior optoFcR activation increased efferocytosis, the engulfment of apoptotic cells. The molecular regulators of efferocytosis partially overlap with antibody-dependent phagocytosis, but the processes require some unique signaling pathways including different ‘eat-me’ signal receptors26. By integrating phosphatidylserine (PS), an efferocytic ‘eat-me’ signal, into the lipid mixture on our silica bead targets, we can recapitulate apoptotic corpse engulfment in vitro27. We incubated PS-coated beads with macrophages at 1 and 12 hours post light stimulation and measured the amount of eating. There was no change in the amount of eating at either time point (Figure 2h). These data suggest that prior FcR activation primes macrophages to specifically react to IgG. This also suggests that the molecular regulators of priming are unique to FcR signaling, rather than in one of the pathways shared by efferocytosis and antibody-dependent phagocytosis.
We then investigated if prior FcR stimulation changed macrophage sensitivity for IgG, lowering the threshold of IgG required for initiating phagocytosis. Alternatively, priming could increase macrophage capacity, the maximum number of targets each macrophage can engulf. To do this, we added beads with various concentrations of IgG to BMDMs and calculated the fold change in phagocytosis (Figure S2g,h). Primed macrophages show enhanced eating of beads with low concentration of IgG. The total capacity for phagocytosis is not significantly changed in primed macrophages. This indicates that priming primarily alters macrophage sensitivity to low levels of IgG, rather than overall capacity for phagocytosis.
Primed macrophages phagocytose more antibody opsonized cancer cells.
We next sought to determine if primed macrophages can increase whole cell eating of opsonized cancer cell targets. In addition to phagocytosis, macrophages often trogocytose or nibble target cells, stripping the cancer cells of target antigen without killing them15. Prior clinical studies have shown that the anti-CD20 therapeutic antibody (rituximab) is most effective when administered more frequently at a low dose, which minimizes antigen shaving28. Given our results, we hypothesized that prior FcR activation might also enhance phagocytosis of cancer cells. We first measured phagocytosis of Raji B cells incubated with increasing concentrations of anti-CD20 antibody to find an antibody concentration where we could detect a change in macrophage sensitivity (Figure S3a-b). To measure both the amount of whole cell phagocytosis and trogocytosis, we incubated IgG opsonized Raji cell targets with primed or unprimed optoFcR-expressing BMDMs and analyzed the cells with timelapse microscopy (Figure 3a-b; Video S4). We found that the number of Raji cells phagocytosed, and the percent of phagocytic macrophages increased in primed macrophages (Figure 3c-d). The percentage of primed macrophages that trogocytosed was not significantly increased compared to unprimed macrophages (Figure 3e). This suggests that primed macrophages are better at phagocytosing antibody-opsonized cancer cells.
Figure 3. Macrophages are primed for increased cancer cell engulfment.

a) Schematic of experimental design for priming with optoFcR and secondary stimulation with cancer cell targets. optoFcR cells were exposed to light for 15 minutes, then returned to the dark. Raji B cells opsonized with 5 ng/ml IgG were added after 12 hours, and the cancer cell-macrophage interactions were captured by timelapse microscopy. b) optoFcR (mSc; green) expressing macrophages phagocytosed and trogocytosed Raji B cells (CellTrace far red; magenta). Yellow arrows point to phagocytosis of a whole cancer cell and white arrows point to trogocytosis of cancer cell fragments. See also video S4. c) Percent of BMDMs that engulfed a whole target cell increased with prior FcR stimulation. d) The number of whole Raji B cells engulfed was greater in primed macrophages. e) Percent of BMDMs that trogocytosed a target was not significantly different with priming. f) Schematic of experimental design for priming and secondary stimulation with cancer cell targets. BMDMs were primed with opsonized (5 ng/ml IgG) or unopsonized Raji B cells for 15 min before Raji B cells were washed out. After 14 hours, a second stimulation of Raji B cells opsonized with 5 ng/ml IgG were introduced and cancer cell-macrophage interactions were imaged with timelapse microscopy. g) Representative images of phagocytosis in each of the three conditions. Raji B cells were visualized using CellTrace far red (magenta) and BMDMs were visualized with CAAX-mCh expression (green). Yellow arrows denote phagocytosis of a whole cancer cell. See also video S5. h) The percent of BMDMs that engulfed a Raji target increased with prior stimulation with opsonized targets compared to stimulation with unopsonized targets or no prior stimulation. i) The number of whole Raji targets engulfed was greater in primed macrophages. j) The percent of BMDMs that trogocytosed was similar in primed macrophages compared to controls. Each data point represents the mean of an independent experiment, denoted by symbol shape, and bars represent the mean ±SEM. *indicates p<0.05, **indicates p<0.005, ****indicates p<0.0001 using an unpaired t-test (c-e) or one way ANOVA with Sidak corrections. See also figure S3.
We then took the experiment a step further and asked if antibody opsonized cancer cells could prime macrophages via the endogenous FcR. We incubated macrophages with either opsonized or unopsonized Rajis for 15 min before washing out the Rajis. 24 hours later, we added opsonized and fluorescently labeled Rajis to all conditions and measured phagocytosis and trogocytosis by timelapse microscopy (Figure 3f,g; Video S5). We found that the endogenous system primed macrophages for more whole cell eating (Figure 3h-j). In contrast, trogocytosis in primed macrophages was fairly similar to unprimed macrophages (Figure 3i). Priming macrophages via the endogenous IgG-FcR system increased phagocytosis even more than priming with the optoFcR system. This data suggests that prior exposure to antibody opsonized cancer cells increases phagocytosis at low IgG densities.
Macrophage priming occurs through a short-term and long-term mechanism.
We next sought to determine the molecular mechanism for enhanced phagocytosis after FcR activation. We observed enhanced phagocytosis at both 1 hour and 12 hours after optoFcR stimulation (Figure 2b). While 12 hours post-stimulation is likely enough time for changes in transcription or translation to affect macrophage phenotypes, 1 hour is likely too short for this mechanism. We decided to carefully assay when macrophage priming occurred. To do this we activated the optoFcR and varied the time before presenting a second stimulus of IgG coated beads and measuring phagocytosis. We saw robust priming occurring in two discrete waves: a short-term response that peaks around 1 hour after FcR activation, and a long-term response that begins at 4 hours after FcR activation and persists for at least 72 hours (Figure 4a).
Figure 4. FcR mediated priming occurs via a short- and long-term mechanism.

a) Phagocytosis of 1nM IgG beads added at the indicated time post 15 min low intensity light stimulation for macrophages expressing the optoFcR (blue) or a control mCh-CAAX (red). Enhanced phagocytosis occurs in two discrete peaks and lasts for at least 72 hours. Points denote the mean of 4 independent replicates. Phagocytosis is normalized to unstimulated control cells. b) Macrophages were treated with Actinomycin D (AD, 10nM) or Cycloheximide (CHX, 10ug/ml) to block transcription or translation respectively starting 7 hours before phagocytosis. Macrophages were stimulated with light to activate the optoFcR at 1, 4 or 6 hours before phagocytosis. AD and CHX did not eliminate priming at 1 hour post-stimulation. AD and CHX eliminated the enhanced phagocytosis phenotype at 4 and 6 hours post stimulation. c) Macrophages were treated with Erk inhibitor (PD0325901, 0.5uM) or DMSO control for 16 hours before measuring phagocytosis. optoFcR macrophages stimulated with light 1 hour before bead addition still showed enhanced phagocytosis. Macrophages stimulated with light 12 hours before bead addition phagocytosed the same number of beads as controls. Phagocytosis is normalized to unstimulated control cells. Each data point represents the mean of an independent experiment. Data collected in the same replicate are denoted by symbol shape. Bars represent the mean ±SEM. *indicates p<0.05, **indicates p<0.005, ***indicates p<0.0005, ****indicates p<0.0001 using a two-way ANOVA with Sidak corrections (a-c).
As the long-term priming following optoFcR activation persists for at least 72 hours, we speculated that this response requires de novo protein production rather than a more transient post-translational modification mechanism. We evaluated priming in macrophages treated with cycloheximide (CHX) and actinomycin D (AD) to inhibit translation and transcription respectively. Treatment with either CHX or AD significantly reduced phagocytosis in primed macrophages compared to DMSO treated control macrophages at 4 and 6 hours post light stimulation (Figure 4b). This suggests that de novo mRNA and protein synthesis is required for a long-term memory response. Blocking new protein synthesis did not significantly reduce priming at 1 hour post stimulation, suggesting that short-term memory is not reliant on new protein production (Figure 4b). Overall this suggests that there are two mechanisms for macrophage priming – one that operates on a short timescale and does not require synthesis of new proteins, and one that operates on a long time scale and requires changes in gene expression.
Erk activation is required for long-term priming.
Because long-term priming requires new protein production, we sought to dissect which transcriptional programs were being executed by the macrophages. Erk, a nuclear kinase, functions downstream of the FcR and regulates the macrophage dose dependent response to LPS as well as many other immune signaling pathways11. To determine if Erk contributes to macrophage priming, we used PD0325901 to block Erk activity. We then stimulated the optoFcR for 15 minutes, waited 1 or 12 hours, and measured phagocytosis of IgG-coated beads. Inhibiting Erk signaling blocked long-term memory with no effect on short-term memory (Figure 4c). These results indicate that long-term priming requires a transcriptional response mediated by Erk activation.
Prior FcR activation increases expression of immune response genes
Since long-term priming requires changes in gene expression, we characterized the transcriptional profile of primed and unprimed macrophages using bulk RNAseq. We found that differentially regulated genes were enriched for Gene Ontology annotations associated with immune response pathways (Figure 5a; Figure S4a). We additionally assessed the polarization of primed macrophages compared to classically polarized M1 and M2 macrophages by RNA sequencing. Primed macrophages resemble M2 polarized macrophages, but have a unique transcriptional profile that does not fully recapitulate either M1 or M2 polarization (Figure 5b; Figure S4b; Table S1).
Figure 5. Transcriptional changes drive priming through an increase in both initiation and completion of phagocytosis.

a) GO analysis of genes that were greater than 1log2 fold differentially expressed in primed macrophages compared to both stimulated control macrophages (lentivirally infected with Caax-mCh) and to unstimulated optoFcR macrophages. Only genes that were differentially expressed in both comparisons were included. b) PCA of primed macrophages gene expression profile compared to M1 polarized (stimulated with LPS and IFN-ɣ) macrophages and M2 polarized (stimulated with IL-4) macrophages. c) optoFcR macrophages received 15 min light stimulus 12 hours before bead addition (primed) and were compared to optoFcR macrophages that did not receive light stimulation (unprimed). Timelapse imaging was used to quantify the kinetics of phagocytosis. Schematic shows each step in phagocytosis: binding (target contact with cell), initiation (formation of the phagocytic cup), and completion (cup closure and bead internalization). Below, the percent of macrophage-bead contacts that progress from one stage to the next. d) Representative images of each stage. White box shows area of inset. Scale bar is 10 um. See also video S6. e) Binding is comparable between primed and unprimed macrophages at 12 hours post stimulation. f) Percent of bead contacts that initiate phagocytosis is higher in primed macrophages at 12 hours after stimulation. g) Time from binding to initiation is not changed 12 hours post stimulation. h) Percent of initiated cups that complete phagocytosis is increased in primed macrophages 12 hours post stimulation. i) Time from initiation to completion is faster in primed macrophages 12 hours after stimulation. j) The overall success rate of phagocytosis is increased in primed macrophages. Each filled data point represents the mean of an independent experiment, denoted by symbol shape, and corresponding outlined data points represent individual bead times. Bars represent the mean ±SEM. *indicates p<0.05, **indicates p<0.005, ***indicates p<0.0005, ****indicates p<0.0001 using an unpaired t-test on the means of each replicate. See also figure S4.
Long-term macrophage priming increases both the frequency of initiating phagocytosis and the speed of completing phagocytosis.
To further understand the effects of the transcriptional changes, we sought to isolate which step in the phagocytic process was enhanced by prior sub-threshold activation of the FcR. To do this, we quantified the kinetics of engulfment using live cell imaging, breaking the process of phagocytosis into three steps: target binding, initiation of phagocytosis, and completion21 (Figure 5c,d; Video S6). We then quantified the time between each step in primed and unprimed macrophages, and the percent of bead contacts that successfully progressed from one step to the next without membrane retraction and target release. We also measured the percent of beads that were bound to macrophages but found no difference between primed and unprimed macrophages (Figure 5e). Primed macrophages were more likely to both initiate and complete phagocytosis and the time between initiation and completion was decreased (Figure 5f-i). Additionally, the overall success of phagocytosis, from bead binding to completion was roughly two-fold higher in primed macrophages (Figure 5j). Stimulated control macrophages that do not express the optoFcR did not show a difference in any measure of phagocytosis compared to unstimulated control macrophages (Figure S4c-h). This suggests that the transcriptional changes that cause long-term priming are affecting phagocytic machinery involved in multiple stages of phagocytosis.
Short-term priming increases the speed and frequency of initiating phagocytosis.
Having demonstrated that short-term priming does not require new protein synthesis like long-term priming, we sought to determine the mechanism for short-term priming. To do this, we repeated the kinetics experiment on cells 1 hour after optoFcR activation (Figure 6a). Primed macrophages were more likely to bind beads and initiate phagocytosis, and the time between bead binding and initiation was less (Figure 6b-d). The increase in bead binding did not correlate with a decrease in CD44 expression, a key protein regulating the pericellular matrix29 (Figure S5b). In contrast, after initiation the chance of successfully completing phagocytosis and the speed of phagocytosis were the same in primed and unprimed macrophages (Figure 6e,f). Overall, the percent of bead contacts that result in successful phagocytic events is significantly increased in primed macrophages (Figure 6f). Stimulated control macrophages that do not express the optoFcR did not show a difference in any measure of phagocytosis compared to unstimulated macrophages (Figure S5a-g). These data indicate that prior sub-threshold FcR activation primes macrophages for faster target recognition and more frequent signal initiation, implicating early phagocytic machinery.
Figure 6. Short term priming is caused by an increase in the speed and frequency of initiating phagocytosis which correlates with an increase in FcR mobility.

a) optoFcR macrophages received a 15 min light stimulus 1 hour before bead addition (primed) and were compared to optoFcR macrophages that did not receive light stimulation (unprimed). Timelapse imaging was used to quantify the kinetics of phagocytosis. Schematic shows each step in phagocytosis: binding (target contact with cell), initiation (formation of the phagocytic cup), and completion (cup closure and bead internalization). Below, the schematic shows percent of macrophage-bead contacts that progress from one stage to the next. b) The percentage of beads bound to primed macrophages is greater in stimulated macrophages. c) Percent of bead contacts that initiate phagocytosis is higher in primed macrophages. d) Time from binding to initiation in optoFcR primed macrophages is decreased compared with unprimed macrophages. e) Probability of completing phagocytosis after initiation is comparable in primed and unprimed macrophages. f) The speed of cup closure is comparable in primed and unprimed macrophages. g) The overall success rate of phagocytosis is higher in primed macrophages compared to unprimed macrophages. h) optoFcR macrophages were primed with a 15 minute light stimulus or were not stimulated. One hour later, we labeled FcRIII (CD16) with a qDot using a FcRIII specific fab, and tracked single FcR molecules for 60 seconds. All tracks from one representative primed and unprimed image are shown. Scale bar is 1 um. i) Quantification of the per image mean jump distance (MJD) of all tracks. FcRs from primed macrophages had greater MJD compared to unprimed macrophages. j) Histogram of MJD from all acquired tracks from primed and unprimed macrophages. Primed macrophages show an increase in the population of FcRs that have a greater MJD than unprimed macrophages. Histogram was smoothed in prism using a second order polynomial with 6 neighbors on each size. k) Examples of ‘free’ and ‘confined’ tracks. l) Quantification of motion type analysis shows the proportion of tracks categorized as ‘free’ (circles) or ‘confined’ (triangles) for individual images. The percent of tracks defined as ‘free’ increases in optoFcR expressing macrophages exposed to light is compared to optoFcR macrophages with no light exposure. m) Quantification of the per image mean diffusion coefficients. Tracks from primed macrophages have a higher diffusion coefficient compared to unprimed macrophages. Each filled data point represents the mean from an independent replicate (b-g) or a single image (i-m), corresponding outlined data points represent individual bead times (d,f). Images were acquired in separate experiments. Bars represent the mean ±SEM. *indicates p<0.05, **indicates p<0.005, ***indicates p<0.0005 using an unpaired t-test (b-g, i, m) or a one-way ANOVA (l). See also figure S5.
Priming is associated with enhanced FcR mobility.
As initiation of phagocytosis is faster in primed macrophages, and our prior data indicated that the molecular regulator of priming was specific to the FcR pathway (Figure 2g-h), we decided to look at FcR mobility. Clustering of IgG, and subsequently FcR, increases the frequency and speed of initiating phagocytosis but not the speed of cup closure, similar to the phenotype we observed in our phagocytosis kinetics analysis21. FcR cluster formation and subsequent activation is dependent on the lateral mobility of FcRs, which is constrained by a heterogeneous F-actin ‘fence’ and other mechanisms29-32. Increased FcR mobility correlates with increased binding of IgG-coated targets and phagocytosis29,31,33. We hypothesized that primed macrophages may have higher FcR mobility, which could explain the increased speed and frequency of initiating phagocytosis. To determine if optoFcR priming increases receptor mobility, we tracked single FcR molecules on optoFcR primed and unprimed cells (Figure 6h). On average, the FcR molecules on primed macrophages had a higher mean jump distance (MJD; average distance traveled between frames) than on unprimed macrophages (Figure 6i). Graphing the MJD of individual tracks, primed macrophages had a multi-modal distribution of track MJDs, suggesting there may be a more mobile population in the primed macrophages (Figure 6j).
Previous studies have described FcR motion as free or confined29,31. Confined FcRs have limited mobility and may not be available to form signaling microclusters required for phagocytosis. To see if primed macrophages had more free FcRs, we categorized FcR tracks by motion type using a moment scaling spectrum (MSS) analysis. MSS categorizes modes of random motion and has previously been used to classify FcR motion types31. Consistent with previous studies, we found a population of confined Fc Receptors that were restricted to small microdomains or ‘corals’ within the membrane (Figure 6k,l)29,31. This population decreased in primed macrophages, suggesting that more FcRs may be available to join signaling micro-clusters. In addition, the average diffusion coefficient, indicative of how far individual receptors travel, was significantly higher in primed macrophages (Figure 6m). Overall, this data suggests that there is an increase in the mobile fraction of FcRs on primed macrophages, which may increase formation of FcR signaling clusters and the probability of initiating phagocytosis.
Discussion
Our work suggests that the macrophage response to IgG integrates information from sequential encounters with IgG coated targets. Prior FcR activation makes macrophages more likely to phagocytose an IgG-coated target. This enhanced phagocytosis correlates with an increase in FcR mobility in the short-term. Long-term priming requires Erk signaling and transcription of new proteins.
Clustering of the FcR has previously been linked to its activation and enhanced phagocytosis21,22,34,35. We recapitulate this clustering using an optogenetic method and find that clustering of the optogenetic FcR is sufficient to drive Syk recruitment, which is indicative of phosphorylation of the intracellular Immunoreceptor Tyrosine-based Activation Motifs (ITAMs). The FcR has no inherent kinase activity, so why does clustering promote receptor activation? ITAM phosphorylation is controlled by the opposing actions of Src family kinases, which favor activation, and transmembrane phosphatases like CD45 that deactivate the receptor1. Prior work has shown that CD45 is excluded from FcR clusters at the phagocytic synapse, and we found that CD45 was also excluded from optoFcR clusters (Figure S1)36-38. CD45 exclusion can be driven by the extracellular domain, which is too bulky to enter the spatially restricted synapse between a macrophage and its target37-39. The CD45 transmembrane domain is also excluded from lipid ordered domains that are enriched in immune receptors and Src kinases, and the intracellular domain is excluded from clusters of purified receptor intracellular domains on a supported lipid bilayer40-42. The optoFcR is myristoylated, so clustering may exclude CD45 due to inclusion of the optoFcR in lipid ordered domains or clustering of the intracellular domain. In addition, there may be factors other than CD45 exclusion that promote optoFcR phosphorylation and activation, like the geometry of the clustered intracellular FcR domains.
Prior work has shown a critical threshold of FcR activation is required for macrophages to commit to phagocytosis10. FcR signaling that is below this threshold activates the initial steps in the phagocytic signaling pathway, including recruitment of the downstream effector kinase Syk10. Whether this low level of activation has any effect on macrophages was not clear. Our data suggests that this low level of activation may have a function in the macrophage, allowing the cell to prepare for future encounters with IgG-bound targets.
In the hour following optoFcR activation, the mobility of native FcRs on the macrophage surface increases. Our working model is that increased FcR mobility increases the formation of receptor clusters that promote initiating and continuing phagocytosis21,33. This could enhance macrophage sensitivity by enabling formation of signaling clusters with a lower overall IgG density. Supporting this model, our kinetic analysis shows that short-term priming enhances the same steps in phagocytosis as ligand clustering (Figure 6)21. FcR mobility is constrained by the actin cytoskeleton and actin-associated transmembrane pickets29,31,32,43. Syk kinase activation rearranges the actin cytoskeleton allowing for less constrained FcR diffusion and greater mobility31. Since the optoFcR also recruits Syk, changes in the actin cytoskeleton may underlie the change in FcR mobility in our system. Prior studies have correlated FcR or IgG mobility with dramatic impacts on phagocytosis29,33. However, our data does not rule out other mechanisms for short-term priming which could synergize with enhanced FcR mobility. For example, we found that bead binding was increased in primed macrophages which could potentially be explained by an increase in FcR mobility, but alternatively could indicate an increase in FcR accessibility29.
Four hours after FcR activation, the macrophage response to IgG relies on changes in gene expression. We found that these changes in gene expression somewhat correlates with M2 differentiation. Macrophage polarization in vivo is known to be more complex than these classic examples, so future studies could determine how exposure to IgG affects the balance of different macrophage subsets. Our kinetics analysis shows that these transcriptional changes drive priming by enhancing multiple stages of phagocytosis, including an increase in the speed of cup closure. This appears to be a different mechanism from the short-term priming, which specifically affects the early stages of phagocytosis - bead binding and initiation.
Our data show that lower levels of optoFcR stimulation prime phagocytosis better than high levels. Prior work has shown that low levels of TLR activation prime macrophages for a rapid and strong response to future stimuli, without activating an inflammatory response alone11. Our study suggests this may be true for the FcR pathway as well. The effect of high levels of FcR activation may be different because it is associated with receptor internalization, which can lead to decreased phagocytic capacity18. Previous studies have shown that phagocytosing many antibody-coated cancer cells causes macrophage ‘hypophagia’ or reduced phagocytosis. This suggests that the signaling consequences of successful phagocytosis and sub-threshold FcR activation may be quite different.
While the adaptive immune system is traditionally thought of as the source of immunological memory, a growing body of evidence shows that the innate immune system also remembers prior infections and threats. This is often called “trained immunity” and occurs via epigenetic reprogramming of myeloid cells to increase or decrease their transcriptional response to reinfection16,44,45. Trained immunity can persist for years if myeloid progenitor cells are affected. Most of the work on trained immunity has focused on a memory of pathogenic molecules or inflammatory cytokines. Our work builds on this, suggesting that FcR activation also elicits a long-term molecular memory driven by Erk dependent transcriptional changes. Whether this memory persists beyond 72 hours will need to be addressed in follow up in vivo studies. In contrast, the short-term priming we describe is distinct from prior descriptions of trained immunity since it does not involve changes in gene expression. We imagine this increased appetite after FcR activation could promote phagocytosis during an infection, when a macrophage is encountering antibody-bound pathogens, while still maintaining a high threshold for activating phagocytosis during homeostasis, when preventing autoimmune disease is a high priority.
The FcR is required for the full efficacy of many cancer immunotherapies, including popular immunotherapies like PD-1 and CTLA-4 blockades9,46. Some therapies, like the anti-CD20 antibody Rituximab, heavily rely on antibody-dependent cellular phagocytosis as a mechanism for eliminating cancer cells4. Interestingly, more frequent low dose treatments of Rituximab are more effective at treating Chronic Lymphocytic Leukemia (CLL) patients than higher dose treatments28. A key reason for this dosing schedule is to mitigate antigen shaving, or trogocytosis of target antigen. Enhancing phagocytosis without increasing antigen shaving is important but difficult. Our data shows that primed macrophages are better at phagocytosing whole cancer cells, but equally likely to trogocytose. This suggests that the current dosing regimen of frequent, low doses may already benefit from the effects of macrophage priming. Additionally, monocytes expressing Chimeric Antigen Receptors that signal through the FcR intracellular signaling domain are an exciting avenue of cancer research47-50. How can we engineer hungrier macrophages to attack cancer cells? Our studies reveal that macrophage priming could enhance phagocytosis or other anti-cancer signaling pathways in these macrophages.
Limitations of the Study
In vivo, there are many specialized macrophage sub-populations. Future studies will need to determine if IgG primes all of these populations using a similar mechanism, or if there are tissue-specific differences. Future studies should also determine if therapeutic monoclonal antibodies prime macrophages in vivo or in human tissues. The FcR family includes activating and inhibiting receptors. The optoFcR models activating receptors, so future studies will need to address the role of inhibitory FcRs in IgG priming.
STAR Methods
Resource Availability
Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Meghan Morrissey (morrissey@ucsb.edu).
Materials Availability
Plasmids generated in this study have been deposited to Addgene or can be obtained from the Lead Contact.
Data and Code Availability
RNA-seq data have been deposited at Dryad and are publicly available as of the date of publication. DOIs are listed in the key resources table. Complete imaging datasets are available from the lead contact upon request.
All original code has been deposited on GitHub and is publicly available as of the date of publication. DOIs are listed in the key resources table.
Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.
Key resources table
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
| Antibodies | ||
| AlexaFlour647 anti-biotin IgG | Jackson ImmunoResearch Laboratories | Cat# 200-602-211, RRID:AB_2339046) |
| Anti-CD20 | InvivoGen | Cat# hcd20-mab10, RRID:AB_11124933 |
| Mouse Anti-CD16/32 | Cell signaling | Cat# 88280 |
| Anti-Rat IgG biotin conjugate | Invitrogen | Cat# 13-4813-85 |
| Anti-CD45 | Cell Signaling | Cat# 70257T |
| Anti-Rabbit 488 | Cell Signaling | Cat# 4412S |
| Anti-CD44 Superbright 600 | Invitrogen | Cat# 63-044-82 |
| Anti-CD64 PerCP-eFuor710 | Invitrogen | Cat# 46-0641-80 |
| Anti-CD16-2 FITC | Invitrogen | Cat# MA-28253 |
| Anti-CD32b APC | Invitrogen | Cat# 17-0321-80 |
| Anti-CD16/32 PE | Biolegend | Cat# 101307 |
| Anti-SIRPa APC/Cy7 | Biolegend | Cat# 144018 |
| Superbright 600 isotype control | Invitrogen | Cat# 634031-82 |
| PerCP-eFuor710 isotype control | Invitrogen | Cat# 46-4714-80 |
| FITC isotype control | Biolegend | Cat# 402307 |
| APC isotype control | Invitrogen | Cat# 17-4724-81 |
| PE isotype control | Invitrogen | Cat# 12-4321-80 |
| APC/Cy7 isotype control | Biolegend | Cat# 400422 |
| Chemicals, peptides, and recombinant proteins | ||
| POPC | Avanti | Cat# 850457 |
| Biotinyl cap PE | Avanti | Cat# 870273 |
| PEG5000-PE | Avanti | Cat# 880230 |
| Atto390-DOPE | ATTO-TEC GmbH | Cat# AD 390-161 |
| Atto647-DOPE | ATTO-TEC GmbH | Cat# AD 647-161 |
| Ni2+-DGS-NTA | Avanti | Cat# 790404 |
| DOPS | Avanti | Cat# 840035 |
| CellTrace Far Red | ThermoFisher | Cat# C34572 |
| CellTrace CSFE | ThermoFisher | Cat# C34570 |
| Qdot 655 | ThermoFisher | Cat# Q10123MP |
| Casein | Sigma | Cat# C5890 |
| PD0325901 - ERK inhibitor | Sigma | Cat# PZ0162 |
| Actinomycin D | Cell signaling | Cat# 15021s |
| Cycloheximide | Cell signaling | Cat# 2112s |
| dNTPs | New England Biolabs | Cat# N0447l |
| RNase OUT | ThermoFisher | Cat# 10777019 |
| Superscript II Reverse Transcriptase | Invitrogen | Cat# 1864014 |
| E. coli DNA Polymerase I | Invitrogen | Cat# 18010025 |
| RNase H | ThermoFisher | Cat# EN0202 |
| DNA magnetic beads | AMPure | Cat# A63882 |
| MEGAscript T7 | Invitrogen | Cat# A57622 |
| ExoSAP IT PCR reagent | Invitrogen | Cat# 78200.200.UL |
| LPS | Sigma | Cat# L4516 |
| IFN-y | Sino Biological | Cat# 50709-MNAH |
| IL-4 | Sino Biological | Cat# 51084-MNAE |
| Critical commercial assays | ||
| Pierce Fab Preparation Kit | ThermoFisher | Cat# 44985 |
| PureLink RNA mini kit | Invitrogen | Cat# 12183018A |
| Experimental models: Cell lines | ||
| Human: HEK239T | ATCC | Cat# ATCC CRL-3216 |
| Mouse: RAW264.7 | ATCC | Cat# ATCC TIB-71; RRID:CVCL_0493 |
| Mouse: L929 | ATCC | Cat# ATCC CLL1; RRID:CVCL_0462 |
| Sf9 | ThermoFisher | Cat# 11496015 |
| Experimental models: Organisms/strains | ||
| Mouse: C57BL/6 | The Jackson Laboratory | Cat# 000664 |
| Recombinant DNA | ||
| pHR-optoFcR | This paper | In pHR vector. Myristolization sequence: MGSSKSKPKDPSQ R; cytoplasmic domain (aa 45–86) of the Fc γ-chain UniProtKB - P20491 (FCERG_MOUSE); linker: STSG; fluorophore: mScarlet; linker: SDPGSGS; Cry2-olig (aa 1-498) of CRY2_ARATH UnitprotKB – Q96524 with E490G mutation followed by: ARDPP (as described in Taslimi et al, 2014) |
| pHR-Syk NeonGreen NK83 | Kern et al.21 | Addgene plasmid # 176610 ; http://n2t.net/addgene:176610 ; RRID:Addgene_176610 |
| pHR mCherry-caax | Morrissey et al.47 | mCherry fused to membrane targeting sequence from KRAB (amino acids LEKMSKDGKKKKK KSKTKCVIM) |
| pMD2.G | pMD2.G was a gift from Didier Trono, Swiss Federal Institute of Technology Lausanne | Addgene plasmid # 12259 ; http://n2t.net/addaene:12259 : RRID:Addgene_12259 |
| pCMV-dR8.2 | pCMV-dR8.2 dvpr was a gift from Bob Weinberg, Whitehead Institute for Biomedical Research | Addgene plasmid # 8455 ; http://n2t.net/addaene:8455 ; RRID:Addgene_8455 |
| ICAM-tagBFP-His10 | O’Donoghue et al.55 | N/A |
| Software and algorithms | ||
| ImageJ -Fiji | NIH | RRID:SCR_002285 https://fiji.sc/ |
| Affinity Designer | Serif | RRID:SCR_016952 |
| Prism | Graphpad | RRID:SCR_002798 |
| TrackMate | Ershov et al.64; Tinevez et al.65 | N/A |
| Moment Scaling Spectrum analysis | This paper | https://github.com/MZW-Lab/Trajectory_Analysis_optoFcR/tree/main; https://doi.org/10.5281/zenodo.12701581 |
| Blind-Analysis-Tools-1.0 | Github | https://github.com/ahtsaJ/Blind-Analysis-Tools |
| JaCoP | Bolte et al.54 | N/A |
| FlowJo 10 | FlowJo | RRID:SCR_008520 |
| RNAseq analysis | Atkins et al.59 | N/A |
| Other | ||
| 5 um silica beads | Bangs Labs | Cat# SS05003 |
| MatriPlate | Brooks | Cat# MGB09-1-2-LG-L |
| LITOS stimulation plate | Hohener et al.53 | N/A |
| Alexa Fluor 647 MESF calibration beads | Bangs Labs | Cat# 647 |
| RNAseq data | This paper | https://doi.org/10.5061/dryad.hx3ffbgp1 |
Experimental Model and Study Participant Details
Bone-marrow derived macrophage cell culture.
Six- to ten-week-old male and female C57BL/6 mice were sacrificed by CO2 inhalation. Hips and femurs were dissected and bone marrow was harvested as described in Weischenfeldt and Porse51. Macrophage progenitors were differentiated for seven days in RPMI-1640, 10% FBS, 1% PSG supplemented with 20% L929- conditioned media at 37°C. Macrophage differentiation was confirmed by flow cytometry identifying CD11b and F4/80 double positive cells. Differentiated BMDMs were used for experiments from days 7 to 11.
Cell lines.
HEK293T cells (ATCC CRL-3216) were obtained from ATCC and were cultured in DMEM, 10% FBS, 1% PSG media at 37°C. RAW264.7 (ATCC TIB-71) cells were obtained from ATCC and were cultured in DMEM, 10% FBS, 1% PSG, 1nM sodium pyruvate.
Lentivirus production and infection.
All constructs were expressed in BMDMs using lentiviral infection. Lentivirus was produced in HEK293T cells transfected with pMD2.G (Gift from Didier Trono, Addgene plasmid # 12259 containing the VSV-G envelope protein), pCMV-dR8.252 (Gift from Bob Weinberg, Addgene plasmid #8455), and a lentiviral backbone vector containing the construct of interest using lipofectamine LTX (Invitrogen, Cat# 15338–100). The media was harvested 72 h post-transfection, filtered through a 0.45 μm filter (Millapore, Cat# SLHVM33RS) and concentrated using LentiX (Takara Biosciences, Cat# 631232). Concentrated lentivirus was added to cells on day 2 of differentiation. Cells were analyzed between days 7-11.
Method Details
Optogenetic stimulation.
Cells receiving low intensity light (5 uW/cm2) and medium intensity light (190 uW/cm2) were stimulated using a LITOS LED illumination plate53 for 15 min. Cells receiving high intensity light were stimulated using the 488 laser at 75% laser power on a spinning disc confocal microscope for 1 s at 20 s intervals for a total of 15 m (1,389 uW/cm2). Intensity was determined using a slide power meter set to measure 450 nm light. Light used to prime cells was low intensity (5 uW/cm2) unless otherwise indicated.
Clustering and colocalization analysis.
Validating optoFcR clustering and Syk colocalization (Figure 1)
50,000 BMDMs expressing the optoFcR were plated in one well of a 96-well glass bottom MatriPlate (Brooks, Cat# MGB096-1-2-LG-L) between 12 and 24 h prior to the experiment. Cells were then continuously imaged with high intensity light stimulation for 30 min and then imaged for another 60 min without light stimulation.
To measure optoFcR and Syk colocalization, 50,000 RAW264.7 macrophages virally infected with both the optoFcR and Syk-NeonGreen (Addgene, Plasmid# 176610) were plated in one well of a 96-well glass bottom MatriPlate (Brooks, Cat# MGB096-1-2-LG-L) between 12 and 24 h prior to the experiment. Cells were then continuously imaged with high intensity light stimulation for 30 min. Colocalization was determined by selecting an ROI at the cell membrane, and measuring the Pearson’s correlation coefficient at the first and last timepoints using the JaCoP plugin in ImageJ54.
optoFcR cluster characterization of CD45 colocalization (Figure S1)
50,000 BMDMs expressing the optoFcR were plated in one well of a 96-well glass bottom MatriPlate (Brooks, Cat# MGB096-1-2-LG-L) between 12 and 24 h prior to the experiment. Cells were then stimulated with low, medium, or high light intensity for 15 min and immediately fixed with 4% PFA. Cells were then imaged with TIRF microscopy. The average number and area of optoFcR clusters was determined using ImageJ with manual selection of clusters.
To visualize CD45, cells were plated and stimulated as above. After fixing, cells were washed in PBS and blocked in PBS + 0.5% BSA for 1 hour. Cells were then incubated in CD45 primary antibody (Cell Signaling, Cat# 70257T) overnight at 4 degrees. Cells were then washed and incubated in anti-rabbit secondary antibody (Cell Signaling, Cat# 4412S) for 2 hours. Cells were imaged with TIRF microscopy and colocalization was determined by a Pearson’s correlation coefficient using the JaCoP plugin in ImageJ54. ROIs were selected across an entire cell membrane.
ICAM-1 protein purification.
ICAM-tagBFP-His1055 was expressed in SF9 or HiFive cells using the Bac-to-Bac baculovirus system as described previously56. Insect cell media containing secreted proteins was harvested 72 h after infection with baculovirus. His10 proteins were purified by using Ni-NTA agarose (QIAGEN, Cat# 30230), followed by size exclusion chromatography using a Superdex 200 10/300 GL column (GE Healthcare, Cat# 17517501). The purification buffer was 150 mM NaCl, 50 mM HEPES pH 7.4, 5% glycerol, 2 mM TCEP.
Supported lipid bilayer coated beads.
SUV preparation
For IgG conjugated beads the following chloroform-suspended lipids were mixed and desiccated overnight to remove chloroform: 98.8% POPC (Avanti, Cat# 850457), 1% biotinyl cap PE (Avanti, Cat# 870273), 0.1% PEG5000-PE (Avanti, Cat# 880230, and 0.1% atto390-DOPE (ATTO-TEC GmbH, Cat# AD 390–161) or 0.1% atto647-DOPE (ATTO-TEC GmbH, Cat# AD 647–161). The lipid sheets were resuspended in PBS, pH7.2 (GIBCO, Cat# 20012050) at 10 mM concentration and stored under inert nitrogen gas.
For ICAM-1 conjugated beads, the following chloroform-suspended lipids were mixed and desiccated overnight to remove chloroform: 97.8% POPC (Avanti, Cat# 850457), 2% DGS-NTA (Avanti, Cat# 790404), 0.1% PEG5000-PE (Avanti, Cat# 880230, and 0.1% atto390-DOPE (ATTO-TEC GmbH, Cat# AD 390–161). The lipid sheets were resuspended in PBS, pH7.2 (GIBCO, Cat# 20012050) and stored under inert gas.
For PS beads the following chloroform-suspended lipids were mixed and desiccated overnight to remove chloroform: 89.8% POPC (Avanti, Cat# 850457), 10% DOPS (Avanti, Cat# 840035), 0.1% PEG5000-PE (Avanti, Cat# 880230, and 0.1% atto390-DOPE (ATTO-TEC GmbH, Cat# AD 390–161). The lipid sheets were resuspended in PBS, pH7.2 (GIBCO, Cat# 20012050) and stored under inert gas.
For all SUVs, the lipids were broken into small unilamellar vesicles via several rounds of freeze-thaws. The lipids were then stored at −80°C under argon. To remove aggregated lipids, the solution was diluted to 2 mM and filtered through a 0.22 uM filter (Millapore, Cat# SLLG013SL) immediately prior to use.
Bead preparation
Silica beads with a 4.89 μm diameter (10% solids, Bangs Labs, Cat# SS05003, Lot # 13427) were washed several times with PBS, mixed with 1mM SUVs in PBS and incubated at room temperature for 30 min with end-over-end mixing to allow for bilayer formation. Beads were then washed with PBS to remove excess SUVs and incubated in 0.2% casein (Sigma, Cat# C5890) in PBS for 15 min before protein coupling (IgG and ICAM-1 beads). For IgG conjugated beads, anti-biotin AlexaFluor647-IgG (Jackson ImmunoResearch Laboratories Cat# 200-602-211, Lot# 156182) was added at 1 nM (final density approx. 10-18 IgG molecules/um2) to a 10x dilution of beads (1% solids), unless otherwise indicated. For ICAM-1 conjugated beads, ICAM-1 was added at 10nM. Proteins were coupled to the bilayer for 30 min at room temperature with end-over-end mixing.
The number of IgG molecules per bead was determined by generating a standard curve using Quantum Alexa Fluor 647 MESF calibration beads (Bangs Labs, Cat# 647) to determine the number of fluorescent molecules per bead. IgG from Jackson Immunoresearch labs is labeled with an average of 3.5-5.5 fluorescent molecules per IgG.
Phagocytosis assay
50,000 BMDMs were plated in one well of a 96-well glass bottom MatriPlate (Brooks, Cat# MGB096-1-2-LG-L) between 12 and 24 h prior to the experiment. ~8 × 105 beads were added to wells and engulfment was allowed to proceed for 15 min. The cells were imaged using spinning disc microscopy (40 × 0.95 NA Plan Apo air) . Internalized particles were identified by their fluorescent supported lipid bilayer, and counted in ImageJ by a blinded analyzer using Blind-Analysis-Tools-1.0 ImageJ plug in.
Inhibitors
For transcription and translation inhibited priming, 10 nM actinomycin D (Cell signaling, Cat# 15021s) or 10 ug/ml cycloheximide (Cell signaling, Cat# 2112s) were added to cells 7 hours prior to the start of the experiment. For Erk inhibited priming, 0.5 uM PD0325901 (Sigma, Cat# PZ0162) was added to cells 16 hours prior to the start of the experiment.
Bead priming
50,000 BMDMs were plated in 1 well of a 96-well glass bottom plate 12-24 hours prior to the start of the experiment. A priming dose of ~8 × 105 atto390 beads conjugated to either 1 nM or 0 nM IgG were added to the wells for 15 min. Any unengulfed beads were washed out 5x with media, then checked with a dissecting microscope to confirm the majority of unengulfed beads had been removed. Then the cells were allowed to recover for 1 hour. ~8 × 105 atto647 beads prepared with the indicated IgG concentrations were then added to the wells and engulfment was allowed to proceed for 15 min in a 37 degree incubator. Cells were dyed with CellTrace CSFE (Thermo, Cat# C34570) imaged and the number of atto647 beads engulfed per cell were counted.
Flow Cytometry
200,000 BMDMs were plated in 1 well of a 12 well glass bottom plate (CellVis, Cat# P12-1.5H-N) 24 hours prior to the start of the experiment and stimulated with low, medium, or high intensity light at 1 or 12 hours prior to the start of the experiment. BMDMs were lifted and then washed in PBS before being resuspended in PBS + 0.5% BSA with the following antibodies for 30 min: CD44 Superbright 600 (Invitrogen, Cat# 63-044-82), Superbright 600 isotype control (Invitrogen, Cat# 634031-82), CD64 PerCP-eFluor 710 (Invitrogen, Cat# 46-0641-80), PerCP-eFluor 710 isotype control (Invitrogen, Cat# 46-4714-80), CD16-2 FITC (Invitrogen, Cat# MA-28253), FITC isotype control (Biolegend, Cat# 402307), CD32b APC (Invitrogen, Cat# 17-0321-80), APC isotype control (Invitrogen, Cat# 17-4724-81), CD16/32 PE (Biolegend, Cat# 101307), PE isotype control (Invitrogen, Cat# 12-4321-80), SIRPa APC/Cy7 (Biolegend, Cat# 144018), APC/Cy7 isotype control (Biolegend, Cat# 400422). Cells were then washed in PBS and analyzed using an Attune NxT (invitrogen). Analysis was completed in FlowJo to assess the median fluorescence intensity of each sample. Compensation was performed using single stain and isotype controls.
Raji eating assay (optoFcR priming).
40,000 BMDMs were plated in 1 well of a 96-well glass bottom plate 24 hours prior to the experiment and stimulated with low intensity LITOS illumination 12 hours prior to the experiment. Raji cells were dyed with CellTrace Far Red (Thermo, Cat# C34572), incubated with a human-mouse hybrid aCD20 (InvivoGen, Cat# hcd20-mab10, 5 ng/ml), added to wells at 40,000 cells per well, and imaged immediately. 25 positions per well were automatically selected and imaged every 3 min for 10 hours. Unless otherwise noted, 100 macrophages were randomly selected and scored by a blind analyzer. Phagocytic macrophages were characterized as BMDMs that engulfed 1 or more whole Raji cell targets. Trogocytic macrophages were characterized as BMDMs that engulfed portions of Raji targets. The number of Raji cells engulfed per 100 macrophages was also counted.
Raji eating assay (Raji priming).
40,000 BMDMs were plated in 1 well of a 96-well glass bottom plate 48 hours prior to the experiment. BMDMs were co-incubated with either control media, Raji cells that were previously incubated with a human-mouse hybrid aCD20 (InvivoGen, Cat# hcd20-mab10, 5 ng/ml), or with unopsonized Raji cells. Plates were spun for 5 min at 300xg to ensure Raji cells reached the BMDMs. Following the spin, priming occurred for 15 min before the remaining Raji cells were thoroughly washed out (~15x). 24 hours after the initial stimulus, Raji cells for the secondary stimulus were dyed with CellTrace Far Red (Thermo, Cat# C34572), incubated with a human-mouse hybrid aCD20 (InvivoGen, Cat# hcd20-mab10, 5 ng/ml), added to wells at 40,000 cells per well, and imaged immediately. 25 positions per well were automatically selected and imaged every 3 min for 10 hours. Unless otherwise noted, 100 macrophages were randomly selected and scored by a blind analyzer. Phagocytic macrophages were characterized as BMDMs that engulfed 1 or more whole Raji cell targets. Trogocytic macrophages were characterized as BMDMs that engulfed portions of Raji targets. The number of Raji cells engulfed per 100 macrophages was also counted.
Gene expression analysis
Macrophage polarization and stimulation.
500,000 BMDMs were plated in 1 well of a 6 well glass bottom plate (CellVis, Cat# P06-1.5H-N) 24 hours prior to the start of the stimulation. For M1 polarized cells, 100 ng/ml LPS (Sigma, Cat# L4516) and 50ng/ml IFN-ɣ (Sino Biological, Cat# 50709-MNAH) were added to the cells for 24 hours. For M2 polarized cells, 20 ng/ml IL-4 (Sino Biological, Cat# 51084-MNAE) was added to the cells for 24 hours. The BMDMs were then collected for RNA extraction. Optogenetic stimulation was performed as previously described in these methods with low intensity light for 15 min and cells were collected for RNA extraction 12 hours after stimulation.
RNA Extraction.
Total RNA was extracted using PureLink RNA mini kit (Invitrogen, Cat#12183018A) according to the manufacturer's protocol.
RNAseq
Bulk mRNA sequencing using the CEL-Seq2 technique was performed on 10 ng of total RNA per sample according to previously established protocol57. Briefly, mRNA fragments were randomly primed and reverse transcribed using dNTPs (New England Biolabs, Cat# N0447l), 0.1 M DTT, RNase OUT (ThermoFisher, Cat# 10777019) and Superscript II Reverse Transcriptase (Invitrogen, Cat# 18064014). Then, cDNA strands were synthesized using dNTPs (New England Biolabs, Cat# N0447l), E. coli DNA Polymerase I (Invitrogen, Cat# 18010025), First Strand Buffer (from Invitrogen Superscript II Reverse Transcriptase, Cat# 18064014), and RNase H (Thermo Scientific, Cat# EN0202). DNA magnetic beads (AMPure, Cat# A63882) were used to purify and size DNA fragments before undergoing in vitro transcription to linearly amplify the mRNA reads using the MEGAscript T7 kit (Invitrogen, Cat# A57622). The amplified RNA was mixed with ExoSAP-IT PCR reagent (Invitrogen, Cat# 78200.200.UL), fragmented using 200 mM Tris-acetate (pH 8.1), 500 mM KOAc, 150 mM MgOAc, and reverse transcribed into cDNA. Second-strand cDNA were ligated to Illumina sequencing adapters and underwent PCR amplification. DNA sizes were selected with an average of about 400 bp with two 0.8x DNA bead cleanups (AMPure, Cat# A63882). DNA libraries were sequenced using the NovaSeq™ 6000 system (Illumina), and raw reads were normalized and mapped to the mouse reference genome mm10 (GRCm38)58.
Analysis was performed as described in Atkins et al, 202459. RNA-seq raw counts were modeled parametrically assuming a negative binomial distribution and p-values were adjusted using the Benjamini and Hochberg method to determine differentially-expressed genes with the DESeq2 package60. The R packages ashr and LIMMA were used to calculate log fold change shrinkage and remove batch effects, respectively61,62. Hierarchical clustering was carried out using ComplexHeatmap in R to identify differentially-expressed genes in the dataset and displayed using z-scores63.
Gene Ontology analysis was performed on geneontology.org with all differentially expressed genes that met our significance threshold. Only GO terms with a significant false discovery rate <0.05 were displayed.
Kinetics of engulfment.
BMDMs were plated as described in the bead engulfment assay 12-24 hours prior to the experiment and stimulated with low intensity LITOS illumination 1 or 12 hours prior to the experiment. Using ND acquisition in Elements, 2-3 positions per well were manually selected. Approximately 4 x 105 beads were added and phagocytosis was imaged at 20 s intervals through 7 z planes for 15 min. Only beads that bound within the first 12 min were counted. Bead binding was determined by counting the number of beads bound to cells in the final frame and is shown as a percentage of total beads.
Receptor labeling and single particle tracking.
Fab generation.
Fabs from rat anti-mouse FcRiii (Cell signaling, Cat# 101307) and rabbit anti-rat biotin conjugated (Invitrogen, Cat# 13-4813-85) were generated using the Pierce Fab Preparation Kit (Thermo, Cat# 44985) according to the manufacturer's protocol. In brief, antibodies were run through a Zeba desalting column to exchange buffers before cleavage with immobilized papain for 3 hours with end over end mixing and digestion was confirmed via SDS-PAGE. Fab fragments were then purified using a NAb Protein A column.
Receptor labeling and imaging.
Single FcRs were labeled as previously described31. In brief, cells were blocked for 5 min in RPMI supplemented with 5% goat serum. Then, cells were incubated with primary fab fragments for 10 min in blocking medium. Next, cells were incubated with biotinylated secondary fab fragments for 10 min. Finally, cells were washed with blocking media and incubated with streptavidin-conjugated Qdot 655 (Thermo, Cat# Q10123MP) for 4 min and immediately imaged. Images were acquired at 10 fps for 1 min using ND acquisition in Elements on a spinning disc confocal microscope.
Tracking.
Tracks and particle mean jump distance were generated using the trackmate plugin on ImageJ64,65. Tracks that were less than 50 frames or that contained gaps greater than 3 frames were discarded from analysis. Motion types and diffusion coefficients were determined using moment scaling spectrum analysis using the formula described in Ewers et al, 200531,66-68. To characterize each particle trajectory as confined or free, we first calculated the moments of displacement. Let represent the radial position vector of trajectory , where where is the total number of timepoints in the trajectory. The moment of displacement is defined by the following equation:
Here, represents the value of the moment, represents the degree of the moment where represents the Euclidean norm and represents the spacing between timepoints where
Moments for each trajectory were calculated for each value of (each moment) and each value of (every possible timepoint spacing). From prior work, we assume that each moment follows the power shift law where represents the scaling coefficient of moment 69. Scaling coefficients for a moment for a trajectory were found by first performing a linear least squares regression to find the slope of vs . Then, using the power shift law, we used the slope obtained via linear least squares regressions and divided it by the moment , with the special case of , , to obtain . This special case was added to avoid fitting errors during the next step of our analysis. Once we obtained a for each moment of a trajectory , we plotted vs. and performed a linear least squares regression to obtain the slope of the line formed by vs. . Calculating and then characterizing each trajectory based off the obtained slope value of vs. is known as moment scaling spectrum (MSS) analysis and is commonly used to characterize diffusion behaviors for small particles66. Near 0 MSS values represent stationary diffusive or confined behavior while MSS values between 0 and 1/2 represent subdiffuse or free behavior. We applied these definitions to our MSS values for each trajectory in order to characterize each trajectory as either confined or free. We were also able to calculate the regular diffusion coefficient for each trajectory using the formula: where indicates the use of the second moment, also referred to as the Mean Square Displacement (MSD), and y0 is the y-axis intercept for the line formed performing a linear least squares regression on vs . All of the code used to perform this analysis is available on GitHub and can be found in the key resources table.
Microscopy.
Images were acquired on a spinning disc confocal microscope (Nikon Ti2-E inverted microscope with a Yokogawa CSU-W1 spinning disk unit and an Orca Fusion BT scMos camera) equipped with a 40 × 0.95 NA Plan Apo air and a 100 × 1.49 NA oil immersion objective. The microscope is also equipped with a piezo Z drive and an OkoLabs stage top incubator for temperature, Co2 and humidity control. TIRF imaging was performed with an iLas2 ring TIRF on the same microscope base and same camera. The microscope was controlled using Nikon Elements.
Quantification and statistical analysis.
Statistical analysis was performed in Prism 8 (GraphPad). The statistical test used is indicated in the relevant figure legend. Sample sizes were predetermined and indicated in the relevant figure legend.
Supplementary Material
Table S1. Normalized gene counts in M1 vs M2 vs primed macrophages, related to figure 5.
Video S1. optoFcR clusters after light stimulation, related to figure 1.
Representative movie of an optoFcR (visualized with mScarlet; white) expressing bone marrow derived macrophage stimulated with high intensity light. Light was on from 0-15 min and was turned off from 15-55 min. Images were taken every 30s.
Video S2. Syk colocalizes with optoFcR clusters, related to figure 1.
Representative movie of a RAW macrophages expressing the optoFcR (mScarlet; green) and Syk-neon (magenta) stimulated with high intensity light for the entire duration of the movie. Images were taken every 30s.
Video S3. optoFcR activation triggers phagocytosis of unopsonized beads, related to figure 1.
Representative movie of an optoFcR (mScarlet; green) expressing bone marrow derived macrophage phagocytosing ICAM conjugated beads (atto390; magenta) with high intensity light stimulation. Light was on for the entire duration of the movie. Images were taken every 30s.
Video S4. optoFcR primed macrophages engulf cancer cell targets, related to figure 3.
Representative movies of optoFcR expressing macrophages (mScarlet; green) interacting with raji cell targets (CellTrace Far Red; magenta). From left to right: primed macrophage phagocytosing a raji cell target, primed macrophage trogocytosing a raji target, unprimed macrophage trogocytosing a Raji target. Images were taken every 3 min.
Video S5. Macrophages primed with Raji B cells engulf cancer cell targets, related to figure 3.
Representative movies of control infected macrophage (mCherry; green) interacting with raji cell targets (CellTrace Far Red; magenta). From left to right: macrophage primed with antibody opsonized rajis phagocytosing multiple raji targets, macrophage primed with unopsonized rajis phagocytosing a raji target, unprimed macrophage phagocytosing a raji target. Priming doses of rajis were added and thoroughly washed out 24 hours prior to the start of imaging. Images were taken every 3 min.
Video S6. optoFcR priming affects multiple steps in phagocytosis, related to figure 5.
Representative movie of an optoFcR expressing macrophage (caax-mCherry and optoFcR-mScarlet; green) phagocytosing a 1nM IgG conjugated bead (atto647; magenta). Movie was generated from a maximum projection of 7 z-stacks, 1.5um apart. Images were taken every 20s.
Highlights:
Oligomerization of FcR-ITAM domains is sufficient to trigger phagocytosis
Prior sub-threshold activation of FcRs enhances antibody dependent phagocytosis
FcR activation increases FcR mobility within one hour
FcR activation increases phagocytosis for days by changing gene expression via Erk
Acknowledgements
We thank members of the Morrissey lab for critical feedback on this manuscript. This work was supported by the UCSB Academic Senate, NIGMS (R35GM146935) and the UC Cancer Research Coordinating Committee (C23CR5592) to M.A.M., the Eunice Kennedy Shriver NICHD (R01HD099517) and the National Human Genome Research Institute (R01HG011013) to S.S.D., and the Eunice Kennedy Shriver NICHD (R01HD10880301) to M.Z.W. A.B. was supported by the Karl Storz Imaging fellowship. J.E.Q.N. was supported by a supplement to C23CR5592, the EUREKA scholars program and the MARC scholars program. A.G. was supported by the MARC scholars program. D.J.A. was supported by the NSF CAREER award (CMMI-CAREER-2048043). Schematics were created with BioRender.com. We thank the NRI-MCDB Microscopy Facility at UCSB, especially the director Ben Lopez for providing advice.
Footnotes
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Competing interests
The authors A.B., M.Z.W. and M.A.M. have filed a patent relating to this material. The authors have no other competing interests.
References
- 1.Freeman SA, and Grinstein S (2014). Phagocytosis: Receptors, signal integration, and the cytoskeleton. Immunological Reviews 262, 193–215. 10.1111/imr.12212. [DOI] [PubMed] [Google Scholar]
- 2.Nimmerjahn F, and Ravetch JV (2008). Fcγ receptors as regulators of immune responses. Nature Reviews Immunology 8, 34–47. 10.1038/nri2206. [DOI] [PubMed] [Google Scholar]
- 3.Gül N, Babes L, Siegmund K, Korthouwer R, Bögels M, Braster R, Vidarsson G, ten Hagen TLM, Kubes P, and van Egmond M (2014). Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J Clin Invest 124, 812–823. 10.1172/JCI66776. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Weiskopf K, and Weissman IL (2015). Macrophages are critical effectors of antibody therapies for cancer. mAbs 7, 303–310. 10.1080/19420862.2015.1011450. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Montalvao F, Garcia Z, Celli S, Breart B, Deguine J, Rooijen NV, and Bousso P (2013). The mechanism of anti-CD20–mediated B cell depletion revealed by intravital imaging. J Clin Invest 123, 5098–5103. 10.1172/JCI70972. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, and Tedder TF (2004). The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. Journal of Experimental Medicine 199, 1659–1669. 10.1084/jem.20040119. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Watanabe M, Wallace PK, Keler T, Deo YM, Akewanlop C, and Hayes DF (1999). Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210. Breast Cancer Research and Treatment 53, 199–207. 10.1023/A:1006145507567. [DOI] [PubMed] [Google Scholar]
- 8.Chen X, Song X, Li K, and Zhang T (2019). FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy. Frontiers in Immunology 10, 292. 10.3389/fimmu.2019.00292. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ, and Ravetch JV (2015). FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis. Cancer Cell 28. [DOI] [PubMed] [Google Scholar]
- 10.Zhang Y, Hoppe AD, and Swanson JA (2010). Coordination of Fc receptor signaling regulates cellular commitment to phagocytosis. Proceedings of the National Academy of Sciences 107, 19332–19337. 10.1073/pnas.1008248107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Gottschalk RA, Martins AJ, Angermann BR, Dutta B, Ng CE, Uderhardt S, Tsang JS, Fraser IDC, Meier-Schellersheim M, and Germain RN (2016). Distinct NF-κB and MAPK Activation Thresholds Uncouple Steady-State Microbe Sensing from Anti-pathogen Inflammatory Responses. Cell Systems 2, 378–390. 10.1016/j.cels.2016.04.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Bettadapur A, Miller HW, and Ralston KS (2020). Biting off what can be chewed: Trogocytosis in health, infection, and disease. Infection and Immunity 88. 10.1128/IAI.00930-19/ASSET/50880292-BFB8-40CC-A318-88FA45997A88/ASSETS/GRAPHIC/IAI.00930-19-F0006.JPEG. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Velmurugan R, Challa DK, Ram S, Ober RJ, and Ward ES (2016). Macrophage-Mediated Trogocytosis Leads to Death of Antibody-Opsonized Tumor Cells. Molecular Cancer Therapeutics 15, 1879–1889. 10.1158/1535-7163.MCT-15-0335. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Beum PV, Peek EM, Lindorfer MA, Beurskens FJ, Engelberts PJ, Parren PWHI, van de Winkel JGJ, and Taylor RP (2011). Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells. Journal of immunology (Baltimore, Md. : 1950) 187, 3438–3447. 10.4049/JIMMUNOL.1101189. [DOI] [PubMed] [Google Scholar]
- 15.Pham T, Mero P, and Booth JW (2011). Dynamics of Macrophage Trogocytosis of Rituximab-Coated B Cells. PLoS One 6, e14498. 10.1371/journal.pone.0014498. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Weavers H, Evans IR, Martin P, and Wood W (2016). Corpse Engulfment Generates a Molecular Memory that Primes the Macrophage Inflammatory Response. Cell 165, 1658–1671. 10.1016/j.cell.2016.04.049. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Sharma P, Vijaykumar A, Raghavan JV, Rananaware SR, Alakesh A, Bodele J, Rehman JU, Shukla S, Wagde V, Nadig S, et al. (2022). Particle uptake driven phagocytosis in macrophages and neutrophils enhances bacterial clearance. Journal of Controlled Release 343, 131–141. 10.1016/j.jconrel.2022.01.030. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Pinney JJ, Rivera-Escalera F, Chu CC, Whitehead HE, Vandermeid KR, Nelson AM, Barbeau MC, Zent CS, and Elliott MR (2020). Macrophage hypophagia as a mechanism of innate immune exhaustion in mAb-induced cell clearance. Blood 136, 2065–2079. 10.1182/BLOOD.2020005571. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Zent CS, and Elliott MR (2017). Maxed out macs: physiologic cell clearance as a function of macrophage phagocytic capacity. The FEBS Journal 284, 1021–1039. 10.1111/febs.13961. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Goodridge HS, Underhill DM, and Touret N (2012). Mechanisms of Fc Receptor and Dectin-1 Activation for Phagocytosis. Traffic 13, 1062–1071. 10.1111/j.1600-0854.2012.01382.x. [DOI] [PubMed] [Google Scholar]
- 21.Kern N, Dong R, Douglas SM, Vale RD, and Morrissey MA (2021). Tight nanoscale clustering of Fcγ receptors using DNA origami promotes phagocytosis. eLife 10. 10.7554/eLife.68311. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Sobota A, Strzelecka-Kiliszek A, Gładkowska E, Yoshida K, Mrozińska K, and Kwiatkowska K (2005). Binding of IgG-Opsonized Particles to FcγR Is an Active Stage of Phagocytosis That Involves Receptor Clustering and Phosphorylation. The Journal of Immunology 175, 4450–4457. 10.4049/jimmunol.175.7.4450. [DOI] [PubMed] [Google Scholar]
- 23.Taslimi A, Vrana JD, Chen D, Borinskaya S, Mayer BJ, Kennedy MJ, and Tucker CL (2014). An optimized optogenetic clustering tool for probing protein interaction and function. Nat Commun 5, 4925. 10.1038/ncomms5925. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Springer TA, and Dustin ML (2012). Integrin inside-out signaling and the immunological synapse. Current Opinion in Cell Biology 24, 107–115. 10.1016/j.ceb.2011.10.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Morrissey MA, Kern N, and Vale RD (2020). CD47 Ligation Repositions the Inhibitory Receptor SIRPA to Suppress Integrin Activation and Phagocytosis. Immunity 53, 290–302.e6. 10.1016/j.immuni.2020.07.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Vorselen D, Kamber RA, Labitigan RLD, Loon AP van, Peterman E, Delgado MK, Lin S, Rasmussen JP, Bassik MC, and Theriot JA (2022). Cell surface receptors TREM2, CD14 and integrin αMβ2 drive sinking engulfment in phosphatidylserine-mediated phagocytosis. Preprint at bioRxiv, 10.1101/2022.07.30.502145 10.1101/2022.07.30.502145. [DOI] [Google Scholar]
- 27.Williamson AP, and Vale RD (2018). Spatial control of Draper receptor signaling initiates apoptotic cell engulfment. J Cell Biol 217, 3977–3992. 10.1083/jcb.201711175. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Williams ME, Densmore JJ, Pawluczkowycz AW, Beum PV, Kennedy AD, Lindorfer MA, Hamil SH, Eggleton JC, and Taylor RP (2006). Thrice-Weekly Low-Dose Rituximab Decreases CD20 Loss via Shaving and Promotes Enhanced Targeting in Chronic Lymphocytic Leukemia1. The Journal of Immunology 177, 7435–7443. 10.4049/jimmunol.177.10.7435. [DOI] [PubMed] [Google Scholar]
- 29.Freeman SA, Vega A, Riedl M, Collins RF, Ostrowski PP, Woods EC, Bertozzi CR, Tammi MI, Lidke DS, Johnson P, et al. (2018). Transmembrane Pickets Connect Cyto- and Pericellular Skeletons Forming Barriers to Receptor Engagement. Cell 172, 305–317.e10. 10.1016/j.cell.2017.12.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Kusumi A, Fujiwara TK, Chadda R, Xie M, Tsunoyama TA, Kalay Z, Kasai RS, and Suzuki KGN (2012). Dynamic Organizing Principles of the Plasma Membrane that Regulate Signal Transduction: Commemorating the Fortieth Anniversary of Singer and Nicolson’s Fluid-Mosaic Model. Annual Review of Cell and Developmental Biology 28, 215–250. 10.1146/annurev-cellbio-100809-151736. [DOI] [PubMed] [Google Scholar]
- 31.Jaumouillé V, Farkash Y, Jaqaman K, Das R, Lowell CA, and Grinstein S (2014). Actin Cytoskeleton Reorganization by Syk Regulates Fcγ Receptor Responsiveness by Increasing Its Lateral Mobility and Clustering. Developmental Cell 29, 534–546. 10.1016/j.devcel.2014.04.031. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Andrews NL, Lidke KA, Pfeiffer JR, Burns AR, Wilson BS, Oliver JM, and Lidke DS (2008). Actin restricts FcepsilonRI diffusion and facilitates antigen-induced receptor immobilization. Nat Cell Biol 10, 955–963. 10.1038/ncb1755. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Jo S, Fischer BR, Cronin NM, Dewi Nurmalasari NP, Loyd YM, Kerkvliet JG, Bailey EM, Anderson RB, Scott BL, and Hoppe AD (2024). Antibody surface mobility amplifies FcγR signaling via Arp2/3 during phagocytosis. Biophys J, S0006-3495(24)00094–8. 10.1016/j.bpj.2024.01.036. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Duchemin AM, Ernst LK, and Anderson CL (1994). Clustering of the high affinity Fc receptor for immunoglobulin G (Fc gamma RI) results in phosphorylation of its associated gamma-chain. J Biol Chem 269, 12111–12117. [PubMed] [Google Scholar]
- 35.Lin J, Kurilova S, Scott BL, Bosworth E, Iverson BE, Bailey EM, and Hoppe AD (2016). TIRF imaging of Fc gamma receptor microclusters dynamics and signaling on macrophages during frustrated phagocytosis. BMC Immunology 17, 5. 10.1186/s12865-016-0143-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Goodridge HS, Reyes CN, Becker CA, Katsumoto TR, Ma J, Wolf AJ, Bose N, Chan ASH, Magee AS, Danielson ME, et al. (2011). Activation of the innate immune receptor Dectin-1 upon formation of a ‘phagocytic synapse.’ Nature 472, 471–475. 10.1038/nature10071. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Bakalar MH, Joffe AM, Schmid EM, Son S, Podolski M, and Correspondence DAF (2018). Size-Dependent Segregation Controls Macrophage Phagocytosis of Antibody-Opsonized Targets. Cell 174, 131–142. 10.1016/j.cell.2018.05.059. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Freeman SA, Goyette J, Furuya W, Woods EC, Bertozzi CR, Bergmeier W, Hinz B, Van Der Merwe PA, Das R, and Grinstein S (2016). Integrins Form an Expanding Diffusional Barrier that Coordinates Phagocytosis. Cell 164, 128–140. 10.1016/j.cell.2015.11.048. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.James JR, and Vale RD (2012). Biophysical mechanism of T-cell receptor triggering in a reconstituted system. Nature 487, 64–69. 10.1038/nature11220. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Stone MB, Shelby SA, Nńñez MF, Wisser K, and Veatch SL (2017). Protein sorting by lipid phase-like domains supports emergent signaling function in b lymphocyte plasma membranes. eLife 6, 1–33. 10.7554/eLife.19891. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Su X, Ditlev JA, Rosen MK, and Vale RD (2017). Reconstitution of TCR signaling using supported lipid bilayers. Methods Mol Biol 1584, 65–76. 10.1007/978-1-4939-6881-7_5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Shelby SA, and Veatch SL (2023). The Membrane Phase Transition Gives Rise to Responsive Plasma Membrane Structure and Function. Cold Spring Harb Perspect Biol, a041395. 10.1101/cshperspect.a041395. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Jaumouillé V, Grinstein S, Jaumouill? V, and Grinstein S (2011). Receptor mobility, the cytoskeleton, and particle binding during phagocytosis. Current Opinion in Cell Biology 23, 22–29. 10.1016/j.ceb.2010.10.006. [DOI] [PubMed] [Google Scholar]
- 44.Netea MG, Domínguez-Andrés J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, Joosten LAB, van der Meer JWM, Mhlanga MM, Mulder WJM, et al. (2020). Defining trained immunity and its role in health and disease. Nat Rev Immunol 20, 375–388. 10.1038/s41577-020-0285-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Tehrani SSH, Kogan A, Mikulski P, and Jansen LET (2023). Remembering foods and foes: emerging principles of transcriptional memory. Cell Death Differ, 1–11. 10.1038/s41418-023-01200-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, et al. (2013). Fc-dependent depletion of tumor-infiltrating regulatory t cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. Journal of Experimental Medicine 210, 1695–1710. 10.1084/jem.20130579. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Morrissey MA, Williamson AP, Steinbach AM, Roberts EW, Kern N, Headley MB, and Vale RD (2018). Chimeric antigen receptors that trigger phagocytosis. eLife 7, e36688. 10.7554/eLife.36688. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, Schmierer M, Gabrusiewicz K, Anderson NR, Petty NE, et al. (2020). Human chimeric antigen receptor macrophages for cancer immunotherapy. Nature Biotechnology 38, 947–953. 10.1038/s41587-020-0462-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Sloas C, Gill S, and Klichinsky M (2021). Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors. Front Immunol 12, 783305. 10.3389/fimmu.2021.783305. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Wang S, Yang Y, Ma P, Zha Y, Zhang J, Lei A, and Li N (2022). CAR-macrophage: An extensive immune enhancer to fight cancer. eBioMedicine 76. 10.1016/j.ebiom.2022.103873. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Weischenfeldt J, and Porse B (2008). Bone Marrow-Derived Macrophages (BMM): Isolation and Applications. Cold Spring Harb Protoc 2008, pdb.prot5080. 10.1101/pdb.prot5080. [DOI] [PubMed] [Google Scholar]
- 52.Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS, Sabatini DM, Chen ISY, Hahn WC, Sharp PA, et al. (2003). Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 9, 493–501. 10.1261/rna.2192803. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Höhener TC, Landolt AE, Dessauges C, Hinderling L, Gagliardi PA, and Pertz O (2022). LITOS: a versatile LED illumination tool for optogenetic stimulation. Sci Rep 12, 13139. 10.1038/s41598-022-17312-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Bolte S, and Cordelières FP (2006). A guided tour into subcellular colocalization analysis in light microscopy. Journal of Microscopy 224, 213–232. 10.1111/j.1365-2818.2006.01706.x. [DOI] [PubMed] [Google Scholar]
- 55.O’Donoghue GP, Pielak RM, Smoligovets AA, Lin JJ, and Groves JT (2013). Direct single molecule measurement of TCR triggering by agonist pMHC in living primary T cells. eLife 2, e00778. 10.7554/eLife.00778. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Hui E, and Vale RD (2014). In vitro membrane reconstitution of the T-cell receptor proximal signaling network. Nat Struct Mol Biol 21, 133–142. 10.1038/nsmb.2762. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Hashimshony T, Senderovich N, Avital G, Klochendler A, de Leeuw Y, Anavy L, Gennert D, Li S, Livak KJ, Rozenblatt-Rosen O, et al. (2016). CEL-Seq2: sensitive highly-multiplexed single-cell RNA-Seq. Genome Biology 17, 77. 10.1186/s13059-016-0938-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Church DM, Schneider VA, Graves T, Auger K, Cunningham F, Bouk N, Chen H-C, Agarwala R, McLaren WM, Ritchie GRS, et al. (2011). Modernizing Reference Genome Assemblies. PLOS Biology 9, e1001091. 10.1371/journal.pbio.1001091. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Atkins DJ, Rosas JM, Månsson LK, Shahverdi N, Dey SS, and Pitenis AA (2024). Survival-Associated Cellular Response Maintained in Pancreatic Ductal Adenocarcinoma (PDAC) Switched Between Soft and Stiff 3D Microgel Culture. ACS Biomater. Sci. Eng 10.1021/acsbiomaterials.3c01079. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Love MI, Huber W, and Anders S (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biology 15, 550. 10.1186/s13059-014-0550-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Stephens M, Carbonetto P, Dai C, Gerard D, Lu M, Sun L, Willwerscheid J, Xiao N, and Zeng M (2023). ashr: Methods for Adaptive Shrinkage, using Empirical Bayes. Version 2.2–63. [Google Scholar]
- 62.Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, and Smyth GK (2015). limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43, e47. 10.1093/nar/gkv007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Gu Z, Eils R, and Schlesner M (2016). Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847–2849. 10.1093/bioinformatics/btw313. [DOI] [PubMed] [Google Scholar]
- 64.Ershov D, Phan M-S, Pylvänäinen JW, Rigaud SU, Le Blanc L, Charles-Orszag A, Conway JRW, Laine RF, Roy NH, Bonazzi D, et al. (2022). TrackMate 7: integrating state-of-the-art segmentation algorithms into tracking pipelines. Nat Methods 19, 829–832. 10.1038/s41592-022-01507-1. [DOI] [PubMed] [Google Scholar]
- 65.Tinevez J-Y, Perry N, Schindelin J, Hoopes GM, Reynolds GD, Laplantine E, Bednarek SY, Shorte SL, and Eliceiri KW (2017). TrackMate: An open and extensible platform for single-particle tracking. Methods 115, 80–90. 10.1016/j.ymeth.2016.09.016. [DOI] [PubMed] [Google Scholar]
- 66.Ferrari R, Manfroi AJ, and Young WR (2001). Strongly and weakly self-similar diffusion. Physica D: Nonlinear Phenomena 154, 111–137. 10.1016/S0167-2789(01)00234-2. [DOI] [Google Scholar]
- 67.Ewers H, Smith AE, Sbalzarini IF, Lilie H, Koumoutsakos P, and Helenius A (2005). Single-particle tracking of murine polyoma virus-like particles on live cells and artificial membranes. Proceedings of the National Academy of Sciences 102, 15110–15115. 10.1073/pnas.0504407102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Jaqaman K, Kuwata H, Touret N, Collins R, Trimble WS, Danuser G, and Grinstein S (2011). Cytoskeletal control of CD36 diffusion promotes its receptor and signaling function. Cell 146, 593–606. 10.1016/j.cell.2011.06.049. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Sbalzarini IF, and Koumoutsakos P (2005). Feature point tracking and trajectory analysis for video imaging in cell biology. J Struct Biol 151, 182–195. 10.1016/j.jsb.2005.06.002. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Table S1. Normalized gene counts in M1 vs M2 vs primed macrophages, related to figure 5.
Video S1. optoFcR clusters after light stimulation, related to figure 1.
Representative movie of an optoFcR (visualized with mScarlet; white) expressing bone marrow derived macrophage stimulated with high intensity light. Light was on from 0-15 min and was turned off from 15-55 min. Images were taken every 30s.
Video S2. Syk colocalizes with optoFcR clusters, related to figure 1.
Representative movie of a RAW macrophages expressing the optoFcR (mScarlet; green) and Syk-neon (magenta) stimulated with high intensity light for the entire duration of the movie. Images were taken every 30s.
Video S3. optoFcR activation triggers phagocytosis of unopsonized beads, related to figure 1.
Representative movie of an optoFcR (mScarlet; green) expressing bone marrow derived macrophage phagocytosing ICAM conjugated beads (atto390; magenta) with high intensity light stimulation. Light was on for the entire duration of the movie. Images were taken every 30s.
Video S4. optoFcR primed macrophages engulf cancer cell targets, related to figure 3.
Representative movies of optoFcR expressing macrophages (mScarlet; green) interacting with raji cell targets (CellTrace Far Red; magenta). From left to right: primed macrophage phagocytosing a raji cell target, primed macrophage trogocytosing a raji target, unprimed macrophage trogocytosing a Raji target. Images were taken every 3 min.
Video S5. Macrophages primed with Raji B cells engulf cancer cell targets, related to figure 3.
Representative movies of control infected macrophage (mCherry; green) interacting with raji cell targets (CellTrace Far Red; magenta). From left to right: macrophage primed with antibody opsonized rajis phagocytosing multiple raji targets, macrophage primed with unopsonized rajis phagocytosing a raji target, unprimed macrophage phagocytosing a raji target. Priming doses of rajis were added and thoroughly washed out 24 hours prior to the start of imaging. Images were taken every 3 min.
Video S6. optoFcR priming affects multiple steps in phagocytosis, related to figure 5.
Representative movie of an optoFcR expressing macrophage (caax-mCherry and optoFcR-mScarlet; green) phagocytosing a 1nM IgG conjugated bead (atto647; magenta). Movie was generated from a maximum projection of 7 z-stacks, 1.5um apart. Images were taken every 20s.
Data Availability Statement
RNA-seq data have been deposited at Dryad and are publicly available as of the date of publication. DOIs are listed in the key resources table. Complete imaging datasets are available from the lead contact upon request.
All original code has been deposited on GitHub and is publicly available as of the date of publication. DOIs are listed in the key resources table.
Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.
Key resources table
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
| Antibodies | ||
| AlexaFlour647 anti-biotin IgG | Jackson ImmunoResearch Laboratories | Cat# 200-602-211, RRID:AB_2339046) |
| Anti-CD20 | InvivoGen | Cat# hcd20-mab10, RRID:AB_11124933 |
| Mouse Anti-CD16/32 | Cell signaling | Cat# 88280 |
| Anti-Rat IgG biotin conjugate | Invitrogen | Cat# 13-4813-85 |
| Anti-CD45 | Cell Signaling | Cat# 70257T |
| Anti-Rabbit 488 | Cell Signaling | Cat# 4412S |
| Anti-CD44 Superbright 600 | Invitrogen | Cat# 63-044-82 |
| Anti-CD64 PerCP-eFuor710 | Invitrogen | Cat# 46-0641-80 |
| Anti-CD16-2 FITC | Invitrogen | Cat# MA-28253 |
| Anti-CD32b APC | Invitrogen | Cat# 17-0321-80 |
| Anti-CD16/32 PE | Biolegend | Cat# 101307 |
| Anti-SIRPa APC/Cy7 | Biolegend | Cat# 144018 |
| Superbright 600 isotype control | Invitrogen | Cat# 634031-82 |
| PerCP-eFuor710 isotype control | Invitrogen | Cat# 46-4714-80 |
| FITC isotype control | Biolegend | Cat# 402307 |
| APC isotype control | Invitrogen | Cat# 17-4724-81 |
| PE isotype control | Invitrogen | Cat# 12-4321-80 |
| APC/Cy7 isotype control | Biolegend | Cat# 400422 |
| Chemicals, peptides, and recombinant proteins | ||
| POPC | Avanti | Cat# 850457 |
| Biotinyl cap PE | Avanti | Cat# 870273 |
| PEG5000-PE | Avanti | Cat# 880230 |
| Atto390-DOPE | ATTO-TEC GmbH | Cat# AD 390-161 |
| Atto647-DOPE | ATTO-TEC GmbH | Cat# AD 647-161 |
| Ni2+-DGS-NTA | Avanti | Cat# 790404 |
| DOPS | Avanti | Cat# 840035 |
| CellTrace Far Red | ThermoFisher | Cat# C34572 |
| CellTrace CSFE | ThermoFisher | Cat# C34570 |
| Qdot 655 | ThermoFisher | Cat# Q10123MP |
| Casein | Sigma | Cat# C5890 |
| PD0325901 - ERK inhibitor | Sigma | Cat# PZ0162 |
| Actinomycin D | Cell signaling | Cat# 15021s |
| Cycloheximide | Cell signaling | Cat# 2112s |
| dNTPs | New England Biolabs | Cat# N0447l |
| RNase OUT | ThermoFisher | Cat# 10777019 |
| Superscript II Reverse Transcriptase | Invitrogen | Cat# 1864014 |
| E. coli DNA Polymerase I | Invitrogen | Cat# 18010025 |
| RNase H | ThermoFisher | Cat# EN0202 |
| DNA magnetic beads | AMPure | Cat# A63882 |
| MEGAscript T7 | Invitrogen | Cat# A57622 |
| ExoSAP IT PCR reagent | Invitrogen | Cat# 78200.200.UL |
| LPS | Sigma | Cat# L4516 |
| IFN-y | Sino Biological | Cat# 50709-MNAH |
| IL-4 | Sino Biological | Cat# 51084-MNAE |
| Critical commercial assays | ||
| Pierce Fab Preparation Kit | ThermoFisher | Cat# 44985 |
| PureLink RNA mini kit | Invitrogen | Cat# 12183018A |
| Experimental models: Cell lines | ||
| Human: HEK239T | ATCC | Cat# ATCC CRL-3216 |
| Mouse: RAW264.7 | ATCC | Cat# ATCC TIB-71; RRID:CVCL_0493 |
| Mouse: L929 | ATCC | Cat# ATCC CLL1; RRID:CVCL_0462 |
| Sf9 | ThermoFisher | Cat# 11496015 |
| Experimental models: Organisms/strains | ||
| Mouse: C57BL/6 | The Jackson Laboratory | Cat# 000664 |
| Recombinant DNA | ||
| pHR-optoFcR | This paper | In pHR vector. Myristolization sequence: MGSSKSKPKDPSQ R; cytoplasmic domain (aa 45–86) of the Fc γ-chain UniProtKB - P20491 (FCERG_MOUSE); linker: STSG; fluorophore: mScarlet; linker: SDPGSGS; Cry2-olig (aa 1-498) of CRY2_ARATH UnitprotKB – Q96524 with E490G mutation followed by: ARDPP (as described in Taslimi et al, 2014) |
| pHR-Syk NeonGreen NK83 | Kern et al.21 | Addgene plasmid # 176610 ; http://n2t.net/addgene:176610 ; RRID:Addgene_176610 |
| pHR mCherry-caax | Morrissey et al.47 | mCherry fused to membrane targeting sequence from KRAB (amino acids LEKMSKDGKKKKK KSKTKCVIM) |
| pMD2.G | pMD2.G was a gift from Didier Trono, Swiss Federal Institute of Technology Lausanne | Addgene plasmid # 12259 ; http://n2t.net/addaene:12259 : RRID:Addgene_12259 |
| pCMV-dR8.2 | pCMV-dR8.2 dvpr was a gift from Bob Weinberg, Whitehead Institute for Biomedical Research | Addgene plasmid # 8455 ; http://n2t.net/addaene:8455 ; RRID:Addgene_8455 |
| ICAM-tagBFP-His10 | O’Donoghue et al.55 | N/A |
| Software and algorithms | ||
| ImageJ -Fiji | NIH | RRID:SCR_002285 https://fiji.sc/ |
| Affinity Designer | Serif | RRID:SCR_016952 |
| Prism | Graphpad | RRID:SCR_002798 |
| TrackMate | Ershov et al.64; Tinevez et al.65 | N/A |
| Moment Scaling Spectrum analysis | This paper | https://github.com/MZW-Lab/Trajectory_Analysis_optoFcR/tree/main; https://doi.org/10.5281/zenodo.12701581 |
| Blind-Analysis-Tools-1.0 | Github | https://github.com/ahtsaJ/Blind-Analysis-Tools |
| JaCoP | Bolte et al.54 | N/A |
| FlowJo 10 | FlowJo | RRID:SCR_008520 |
| RNAseq analysis | Atkins et al.59 | N/A |
| Other | ||
| 5 um silica beads | Bangs Labs | Cat# SS05003 |
| MatriPlate | Brooks | Cat# MGB09-1-2-LG-L |
| LITOS stimulation plate | Hohener et al.53 | N/A |
| Alexa Fluor 647 MESF calibration beads | Bangs Labs | Cat# 647 |
| RNAseq data | This paper | https://doi.org/10.5061/dryad.hx3ffbgp1 |
